Related Experiment Video
Updated: Jan 3, 2026

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
Long Non-coding RNA LINC01787 Drives Breast Cancer Progression via Disrupting miR-125b Generation
Yongzhen Li1, Ying Song1, Zhihui Wang2
1Department of Pathology, Xinxiang Medical University, Xinxiang, China.
Abstract:
Breast cancer is still the most common and leading cause of cancer-related deaths in women worldwide. Long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) have shown key regulator roles in various cancers. Previous reports have identified miR-125b as a critical tumor suppressor in breast cancer. However, the role of lncRNAs in breast cancer is far from well-characterized. In this study, we identified a novel lncRNA LINC01787, which specifically binds pre-miR-125b, inhibits the binding between DICER and pre-miR-125b, represses the processing of pre-miR-125b by DICER, and therefore induces pre-miR-125b accumulation and represses mature miR-125b generation. Functional assays showed that LINC01787 promotes breast cancer cell proliferation and migration and breast cancer xenograft growth in vivo, which is abolished by the mutation of pre-miR-125b binding sites on LINC01787 or overexpression of miR-125b. Furthermore, LINC01787 is up-regulated in breast cancer tissues and is associated with advanced stages and poor survival. The expression of LINC01787 is inversely associated with that of miR-125b in breast cancer tissues. In conclusion, our findings identified a novel up-regulated and oncogenic lncRNA LINC01787 in breast cancer, which binds pre-miR-125b and represses mature miR-125b generation. Our data suggests LINC01787 as a potential prognostic biomarker and therapeutic target for breast cancer.
Insights
Researchers identified a new long noncoding RNA (lncRNA), LINC01787, that promotes breast cancer growth by blocking tumor-suppressing miR-125b. This lncRNA may serve as a prognostic biomarker and therapeutic target for breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Breast cancer remains a leading cause of cancer-related deaths globally.
- Long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) are critical regulators in cancer.
- miR-125b is a known tumor suppressor in breast cancer, but the role of lncRNAs is less understood.
Purpose of the Study:
- To identify and characterize novel lncRNAs involved in breast cancer pathogenesis.
- To elucidate the molecular mechanism of LINC01787 in breast cancer.
- To evaluate LINC01787 as a potential biomarker and therapeutic target.
Main Methods:
- Identification of LINC01787 in breast cancer tissues.
- Investigation of LINC01787's interaction with pre-miR-125b and DICER.
- Functional assays including cell proliferation, migration, and xenograft growth.
- Correlation analysis of LINC01787 and miR-125b expression with clinical data.
Main Results:
- LINC01787 was identified as a novel lncRNA that binds pre-miR-125b, inhibiting its processing by DICER and reducing mature miR-125b levels.
- LINC01787 overexpression promoted breast cancer cell proliferation, migration, and tumor growth in vivo.
- LINC01787 is upregulated in breast cancer tissues and associated with advanced stages and poor patient survival.
- Inverse correlation observed between LINC01787 and miR-125b expression in breast cancer tissues.
Conclusions:
- LINC01787 is an oncogenic lncRNA that promotes breast cancer by suppressing miR-125b maturation.
- LINC01787 represents a potential prognostic biomarker and therapeutic target for breast cancer treatment.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
MicroRNAs
MicroRNAs
Non-LTR Retrotransposons
Experimental RNAi
